Literature DB >> 24266248

[Celiac disease--the chameleon among the food intolerances].

Alexander Ströhle1, Maike Wolters, Andreas Hahn.   

Abstract

Celiac disease is an autoimmune disorder resulting from gluten intolerance and is based on a genetically predisposition. Symptoms occur upon exposure to prolamin from wheat, rye, barley and related grain. The pathogenesis of celiac disease has not yet been sufficiently elucidated but is being considered as an autoimmune process. At its core are the deamidation of prolamin fragments, the building of specific antibodies and the activation of cytotoxic T-cells. The immunological inflammatory process is accompanied by structural damages of the enterocytes (villous atrophy, colonization and crypt hyperplasia). The symptoms and their extent depend on the type of the celiac disease; classic and non-classic forms are being distinguished (atypical, oligosymptomatic, latent and silent celiac disease). Characteristics of the classic presentation are malabsorption syndrome and intestinal symptoms such as mushy diarrhea and abdominal distension. The diagnosis of celiac disease is based on four pillars: Anamnesis and clinical presentation, serological evidence of coeliac specific antibodies (IgA-t-TG; IgA-EmA), small intestine biopsy and improvement of symptoms after institution of a gluten-free diet. The basis of the therapy is a lifelong gluten-free diet, i. e. wheat, rye, barley, spelt, green-core, faro-wheat, kamuth and conventional oats as well as food items obtained therefrom. Small amounts of up to 50 mg gluten per day are usually tolerated by most patients; amounts of > or = 100 mg/day lead mostly to symptoms. Gluten-free foods contain < or = 20 ppm or 20 mg/kg (Sign: symbol of the 'crossed ear' or label 'gluten-free'). At the beginning of the therapy the fat and lactose intake may need to be reduced; also the supplementation of single micronutrients (fat-soluble vitamins, folic acid, B12, iron, and calcium) may be required. Alternative therapies are being developed but have not yet been clinically tested.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24266248

Source DB:  PubMed          Journal:  Med Monatsschr Pharm        ISSN: 0342-9601


  4 in total

1.  Rye affects bacterial translocation, intestinal viscosity, microbiota composition and bone mineralization in Turkey poults.

Authors:  Guillermo Tellez; Juan D Latorre; Vivek A Kuttappan; Billy M Hargis; Xochitl Hernandez-Velasco
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

2.  Current knowledge and "myths" about celiac disease among physicians in the Republic of Kazakhstan: A countrywide cross-sectional study.

Authors:  Aizhan Kozhakhmetova; Serzhan Aidossov; Aissulu Kapassova; Karlygash Borsoldayeva
Journal:  Front Public Health       Date:  2022-08-12

3.  Utilization of rye as energy source affects bacterial translocation, intestinal viscosity, microbiota composition, and bone mineralization in broiler chickens.

Authors:  Guillermo Tellez; Juan D Latorre; Vivek A Kuttappan; Michael H Kogut; Amanda Wolfenden; Xochitl Hernandez-Velasco; Billy M Hargis; Walter G Bottje; Lisa R Bielke; Olivia B Faulkner
Journal:  Front Genet       Date:  2014-09-25       Impact factor: 4.599

Review 4.  The opioid effects of gluten exorphins: asymptomatic celiac disease.

Authors:  Leo Pruimboom; Karin de Punder
Journal:  J Health Popul Nutr       Date:  2015-11-24       Impact factor: 2.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.